Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention

“…South Asians are particularly prone to CVD and CVD-related mortality ( 61 – 63 ), and, given that an overwhelming majority of patients in REDUCE-IT were White, Krishnaraj et al ( 50 ) sought to determine the generalizability of the REDUCE-IT results in the secondary prevention setting—using the Health Canada IPE label, the Canadian Cardiovascular Society dyslipidemia guidelines, the US FDA IPE label, and REDUCE-IT criteria—to 200 South Asian patients treated with statins aged forty-five years or older with ASCVD from community cardiology and family practice clinics living in Canada. Overall, ninety-five percent of patients had CAD, eighty-six percent underwent coronary revascularization, forty percent had a history of MI, and seventy-five percent were taking high-dose statins.…”

“…Per the Health Canada IPE label ( 64 ), IPE is indicated for patients with elevated TG levels, with increased CV risk due to established CVD, or diabetes and at least one other CV risk factor. Although the Health Canada label did not denote a TG threshold ( 64 ), Krishnaraj et al ( 50 ) specified a TG threshold of 135 mg/dl or higher to represent hypertriglyceridemia. The Canadian Cardiovascular Society dyslipidemia guidelines recommend IPE for patients with TG levels 135 to 499 m/dl ( 37 ).…”